Activating Native Tumor Immunity with IL-33 Armored CARs
使用 IL-33 装甲 CAR 激活天然肿瘤免疫
基本信息
- 批准号:10744438
- 负责人:
- 金额:$ 57.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive TransferAntigen ReceptorsAntigen TargetingAntigensAntitumor ResponseAutoimmune DiseasesCAR T cell therapyCCR5 geneCXCR6 geneCell SurvivalCellsClinicColonColon CarcinomaCytokine ReceptorsDrug or chemical Tissue DistributionEffector CellFlow CytometryHIF1A geneImageImmuneImmunomodulatorsImmunosuppressionImmunotherapyInfiltrationInterferon Type IIInterleukin-12Interleukin-2InvestigationKineticsLeukocytesLiquid substanceMC38MHC Class I GenesMacrophageMalignant Epithelial CellMalignant NeoplasmsMediatingMetastatic MelanomaMethodsModelingMolecularMyeloid CellsNatural Killer CellsNaturePathway AnalysisPeptide/MHC ComplexPeripheralPopulationRaceRegulatory T-LymphocyteReportingRoleSafetySolidSolid NeoplasmSpatial DistributionT-LymphocyteTestingTissuesToxic effectTumor ImmunityTumor-associated macrophagesanti-tumor immune responsecancer immunotherapycancer therapychemokine receptorchimeric antigen receptorchimeric antigen receptor T cellsclinical translationcytokinedelivery vehicledraining lymph nodeeffector T cellimmunogenicimprovedin vivoluminescencelung metastaticmouse modelneoantigensneoplastic cellnovelperforinrecruittraffickingtranscriptomicstumortumor growthtumor microenvironmenttumor-immune system interactions
项目摘要
ABSTRACT
Unlike liquid cancers, current CAR T cell immunotherapies have little effect against solid cancers, largely due to
the immunosuppressive nature of the tumor microenvironment. The race between administered CAR T cells and
tumor associated cells to kill off and/or neutralize the other is tipped heavily in favor of the tumor. Heterogeneous
tumors or tumors able to shed or downregulate CAR-targeted antigens can also escape elimination by functional
CAR T cell effectors. We recently found that CAR T cells delivery of dual cytokines can enlist and activate
endogenous T cells, NK cells and myeloid cells to mount an effective anti-tumor immune response. Further
investigation revealed that perforin and IFNγ are dispensable in CAR T cells, supporting an accessory role for
CAR T cells in mobilizing endogenous immune cells to ultimately control tumor growth. CAR T cell-mediated
dual cytokine delivery was effective in controlling tumor growth with 3 different CAR T cell constructs and 4 in
vivo tumor models: primary and metastatic melanoma and primary colon cell carcinoma mouse models, and
importantly was impervious to antigen loss. This suggests that the dual cytokine platform has potential for
universal application against multiple solid tumor types. In this application, we hypothesize that CAR T cell
delivery of dual cytokines has broad application because it counteracts immunosuppressive innate and adaptive
immune cells to elicit a broad endogenous anti-tumor response independent of CAR effector potential. We will
test this hypothesis by identifying CAR T cell survival and distribution dynamics (Aim 1), identify the common
and tumor-specific changes in immunosuppressive, immunostimulatory and effector leukocyte populations
isolated from poorly and strongly immunogenic tumors pre- and post-CAR cytokine treatment (Aim 2), and
determine their roles in activating endogenous tumor immunity (Aim 3). The cellular and mechanisms identified
will support further improvement and clinical translation of the Super2+IL-33 platform with various CAR targeting
constructs for CAR T cell therapies for solid tumors.
摘要
与液体癌症不同,目前的CAR T细胞免疫疗法对实体癌症几乎没有效果,这主要是由于
肿瘤微环境的免疫抑制性质。给予的CAR T细胞和
肿瘤相关细胞杀死和/或中和另一种的倾向严重有利于肿瘤。异构
肿瘤或能够脱落或下调CAR靶向抗原的肿瘤也可以通过功能性免疫抑制而逃避消除。
CAR T细胞效应子。我们最近发现,CAR T细胞递送双重细胞因子可以招募和激活
在一些实施方案中,免疫抑制剂可以包括内源性T细胞、NK细胞和骨髓细胞,以产生有效的抗肿瘤免疫应答。进一步
研究表明,穿孔素和IFNγ在CAR T细胞中是可有可无的,支持其辅助作用
CAR T细胞动员内源性免疫细胞,最终控制肿瘤生长。CAR T细胞介导
双重细胞因子递送在控制肿瘤生长方面是有效的,用3种不同的CAR T细胞构建体和4种不同的CAR T细胞构建体。
体内肿瘤模型:原发性和转移性黑素瘤和原发性结肠细胞癌小鼠模型,和
重要的是不受抗原损失的影响。这表明双重细胞因子平台具有潜在的
普遍适用于多种实体瘤类型。在本申请中,我们假设CAR T细胞
双重细胞因子的递送具有广泛的应用,因为它抵消了先天性和适应性免疫抑制
在一些实施方案中,CAR可以与免疫细胞结合,以引起广泛的内源性抗肿瘤应答,而不依赖于CAR效应子潜力。我们将
通过鉴定CAR T细胞存活和分布动力学来测试这一假设(目的1),
以及免疫抑制、免疫刺激和效应白细胞群的肿瘤特异性变化
从CAR细胞因子治疗前和治疗后的免疫原性差和免疫原性强的肿瘤中分离(Aim 2),和
确定它们在激活内源性肿瘤免疫中的作用(目的3)。细胞和机制确定
将支持具有各种CAR靶向的Super 2 +IL-33平台的进一步改进和临床转化
用于实体瘤的CAR T细胞疗法的构建体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yina Hsing Huang其他文献
Yina Hsing Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yina Hsing Huang', 18)}}的其他基金
Directing Cytokine Specificity Through Co-translational Carrier Coupling
通过共翻译载体偶联指导细胞因子特异性
- 批准号:
10581947 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
PIP3-INDEPENDENT REGULATION OF AKT1 ACTIVITY IN T CELLS
T 细胞中 AKT1 活性的 PIP3 独立调节
- 批准号:
8225208 - 财政年份:2011
- 资助金额:
$ 57.35万 - 项目类别:
PIP3-INDEPENDENT REGULATION OF AKT1 ACTIVITY IN T CELLS
T 细胞中 AKT1 活性的 PIP3 独立调节
- 批准号:
8788798 - 财政年份:2011
- 资助金额:
$ 57.35万 - 项目类别:
Novel Requirements for Akt1 in T Cell Commitment
T 细胞承诺中对 Akt1 的新要求
- 批准号:
9405831 - 财政年份:2011
- 资助金额:
$ 57.35万 - 项目类别:
Novel Requirements for Akt1 in T Cell Commitment
T 细胞承诺中对 Akt1 的新要求
- 批准号:
9246741 - 财政年份:2011
- 资助金额:
$ 57.35万 - 项目类别:
Novel Requirements for Akt1 in T Cell Commitment
T 细胞承诺中对 Akt1 的新要求
- 批准号:
10077817 - 财政年份:2011
- 资助金额:
$ 57.35万 - 项目类别:
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别:
Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10321545 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别: